

# Hector Chinoy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/713848/publications.pdf>

Version: 2024-02-01

199  
papers

7,017  
citations

93792

39  
h-index

78623

77  
g-index

204  
all docs

204  
docs citations

204  
times ranked

6622  
citing authors

#	ARTICLE	IF	CITATIONS
1	Limb girdle muscular dystrophy R12 (LGMD 2L, anoctaminopathy) mimicking idiopathic inflammatory myopathy: key points to prevent misdiagnosis. <i>Rheumatology</i> , 2022, 61, 1645-1650.	0.9	10
2	Contribution of Rare Genetic Variation to Disease Susceptibility in a Large Scandinavian Myositis Cohort. <i>Arthritis and Rheumatology</i> , 2022, 74, 342-352.	2.9	7
3	Adult idiopathic inflammatory myopathies. <i>Medicine</i> , 2022, 50, 70-75.	0.2	4
4	COVID-19 vaccination in autoimmune disease (COVAD) survey protocol. <i>Rheumatology International</i> , 2022, 42, 23-29.	1.5	37
5	A systematic review and meta-analysis of mycobacterial infections in patients with idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2022, 61, 3521-3533.	0.9	5
6	Vaccine hesitancy in patients with autoimmune diseases: Data from the coronavirus disease-2019 vaccination in autoimmune diseases study. <i>Indian Journal of Rheumatology</i> , 2022, 17, 188.	0.2	14
7	The role of protein aggregation in the pathogenesis of inclusion body myositis.. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 414-424.	0.4	5
8	The perils of myositis mimickers with illustrative case reports. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 366-372.	0.4	1
9	Investigating characteristics of idiopathic inflammatory myopathy flares using daily symptom data collected via a smartphone app. <i>Rheumatology</i> , 2022, 61, 4845-4854.	0.9	4
10	British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. <i>Rheumatology</i> , 2022, 61, 1760-1768.	0.9	37
11	The perils of myositis mimickers with illustrative case reports.. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 366-372.	0.4	0
12	The origins, evolution and future of the International Myositis Assessment and Clinical Studies Group (IMACS).. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 214-218.	0.4	0
13	The role of protein aggregation in the pathogenesis of inclusion body myositis.. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 414-424.	0.4	0
14	P222 Clinical features of extra-muscular disease in dermatomyositis and anti-synthetase syndrome patients with skin involvement classified by presence of disease-specific autoantibodies: results from the EuroMyositis registry. <i>Rheumatology</i> , 2022, 61, .	0.9	0
15	COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study. <i>Rheumatology</i> , 2022, 62, 65-76.	0.9	19
16	Similar risk of cardiovascular events in idiopathic inflammatory myopathy and rheumatoid arthritis in the first 5 years after diagnosis. <i>Clinical Rheumatology</i> , 2021, 40, 231-238.	1.0	11
17	Focal hamstring muscle oedema and atrophy post-anterior cruciate ligament reconstruction mimicking focal myositis. <i>Rheumatology</i> , 2021, 60, 984-985.	0.9	0
18	COVID-19 and myositis – unique challenges for patients. <i>Rheumatology</i> , 2021, 60, 907-910.	0.9	39

#	ARTICLE	IF	CITATIONS
19	Relapsing polychondritis of the nose and lower respiratory tract. <i>Rheumatology</i> , 2021, 60, e41-e43.	0.9	1
20	In Pursuit of an Effective Treatment: the Past, Present and Future of Clinical Trials in Inclusion Body Myositis. <i>Current Treatment Options in Rheumatology</i> , 2021, 7, 63-81.	0.6	3
21	A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2021, 60, 2615-2628.	0.9	69
22	Efficacy and Safety of Bimagrumb in Sporadic Inclusion Body Myositis. <i>Neurology</i> , 2021, 96, e1595-e1607.	1.5	25
23	Analysis of human total antibody repertoires in TIF1 $\beta$ autoantibody positive dermatomyositis. <i>Communications Biology</i> , 2021, 4, 419.	2.0	9
24	P150 Hand-held dynamometry may provide a valid and objective method of muscle strength quantification in adult inflammatory myopathy: results from clinical practice in a tertiary centre. <i>Rheumatology</i> , 2021, 60, .	0.9	1
25	The avalanche of antirheumatic therapy and COVID-19 vaccinations. <i>Rheumatology</i> , 2021, 60, 3490-3491.	0.9	2
26	P156 Myositis flares are associated with reduced work productivity and fewer hours worked: illustration of the future potential of digital healthcare solutions in rheumatic diseases. <i>Rheumatology</i> , 2021, 60, .	0.9	0
27	P192 Secukinumab provides rapid and sustained improvements in subgroup analyses of joint tenderness and swelling in patients with psoriatic arthritis: 2-year results from the Phase 3 FUTURE 5 study. <i>Rheumatology</i> , 2021, 60, .	0.9	0
28	POS0288...A KEY TIF1 $\beta$ EPI TOPE MAY FACILITATE THE IDENTIFICATION OF PATIENTS AT HIGHEST RISK OF CANCER ASSOCIATED MYOSITIS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 369.2-370.	0.5	0
29	Perspectives on glucocorticoid usage in patients with adult inflammatory myopathy. <i>Clinical Rheumatology</i> , 2021, 40, 4977-4982.	1.0	1
30	The relationship between rheumatoid arthritis and diabetes mellitus: a systematic review and meta-analysis. <i>Cardiovascular Endocrinology and Metabolism</i> , 2021, 10, 125-131.	0.5	25
31	Antibody responses to single dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease. <i>British Journal of Dermatology</i> , 2021, 185, 646-648.	1.4	30
32	Myogenic Cell Transplantation in Genetic and Acquired Diseases of Skeletal Muscle. <i>Frontiers in Genetics</i> , 2021, 12, 702547.	1.1	18
33	The challenges of antirheumatic therapy and travel-associated infections. <i>Rheumatology</i> , 2021, , .	0.9	0
34	Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre. <i>Rheumatology</i> , 2021, 60, 3398-3403.	0.9	27
35	Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1275-1287.	5.2	394
36	Inflammatory Arthropathy in the Elite Sports Athlete. <i>Current Sports Medicine Reports</i> , 2021, 20, 577-583.	0.5	2

#	ARTICLE	IF	CITATIONS
37	Diagnosis of spinal tuberculosis in an Asian patient with unexplained chronic back pain. <i>Rheumatology</i> , 2021, , .	0.9	2
38	The myositis clinical phenotype associated with anti-Zo autoantibodies: a case series of nine UK patients. <i>Rheumatology</i> , 2020, 59, 1626-1631.	0.9	10
39	O33â€fEarlier cancer diagnosis after myositis onset is associated with improved long term survival: results from UK, French and Czech cohorts. <i>Rheumatology</i> , 2020, 59, .	0.9	0
40	P72â€fMuscle weakness affects function differently in males and females in inclusion body myositis: providing results for focused clinical care and clinical trial design. <i>Rheumatology</i> , 2020, 59, .	0.9	0
41	P253â€fSecukinumab provides sustained improvements in tender and swollen joint counts: 5year results from the Phase 3 FUTURE 2 study. <i>Rheumatology</i> , 2020, 59, .	0.9	0
42	P254â€fSecukinumab provides rapid and sustained improvement in joint tenderness and swelling in patients with PsA: 2-year results from the Phase 3 FUTURE 5 study. <i>Rheumatology</i> , 2020, 59, .	0.9	0
43	Monitoring disease activity and damage in adult and juvenile idiopathic inflammatory myopathy. <i>Current Opinion in Rheumatology</i> , 2020, 32, 553-561.	2.0	11
44	Patient insights on living with idiopathic inflammatory myopathy and the limitations of disease activity measurement methods â€c a qualitative study. <i>BMC Rheumatology</i> , 2020, 4, 47.	0.6	9
45	Line blot immunoassays in idiopathic inflammatory myopathies: retrospective review of diagnostic accuracy and factors predicting true positive results. <i>BMC Rheumatology</i> , 2020, 4, 28.	0.6	16
46	Response to: â€Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5 positive dermatomyositis associated rapidly progressive interstitial lung diseases: a challenge for the futureâ€™ by Wang et al. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2020-218712.	0.5	4
47	Insights into the knowledge, attitude and practices for the treatment of idiopathic inflammatory myopathy from a cross-sectional cohort survey of physicians. <i>Rheumatology International</i> , 2020, 40, 2047-2055.	1.5	7
48	MicroRNA and mRNA profiling in the idiopathic inflammatory myopathies. <i>BMC Rheumatology</i> , 2020, 4, 25.	0.6	12
49	Can machine learning unravel the complex IIM spectrum?. <i>Nature Reviews Rheumatology</i> , 2020, 16, 299-300.	3.5	4
50	Longâ€term strength and functional status in inclusion body myositis and identification of trajectory subgroups. <i>Muscle and Nerve</i> , 2020, 62, 76-82.	1.0	21
51	Pitfalls in the diagnosis of myositis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101486.	1.4	17
52	Association of Pharmacological Biomarkers with Treatment Response and Longterm Disability in Patients with Psoriatic Arthritis: Results from OUTPASS. <i>Journal of Rheumatology</i> , 2020, 47, 1204-1208.	1.0	10
53	Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis. <i>Rheumatology</i> , 2020, 59, 1026-1030.	0.9	16
54	Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1383-1386.	0.5	59

#	ARTICLE	IF	CITATIONS
55	Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Myopathy. <i>Journal of Clinical Rheumatology</i> , 2020, 26, e230-e231.	0.5	0
56	Myositis Basics/Who Gets Myositis. , 2020, , 7-15.		0
57	SAT0631-HPR...WHEN CAN I STOP MY STEROIDS? THE PATIENT PERSPECTIVE ON GLUCOCORTICOID USAGE IN ADULT INFLAMMATORY MYOPATHY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1275.1-1276.	0.5	0
58	OP0094...EULAR-ACR 2019 CLASSIFICATION CRITERIA FOR SLE: CAN WE CLASSIFY USING LABORATORY TESTS ALONE?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 62.2-62.	0.5	0
59	SAT0331...CHIPPING AWAY AT POLYMYOSITIS: A RETROSPECTIVE REVIEW AT A TERTIARY MYOSITIS CENTRE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1111-1112.	0.5	1
60	Including myositis-specific autoantibodies improves performance of the idiopathic inflammatory myopathies classification criteria. <i>Rheumatology</i> , 2019, 58, 2331-2333.	0.9	4
61	Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. <i>Lancet Neurology</i> , The, 2019, 18, 834-844.	4.9	91
62	Comment on: The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis: Reply. <i>Rheumatology</i> , 2019, 58, 2073-2074.	0.9	3
63	Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing. <i>PLoS ONE</i> , 2019, 14, e0218115.	1.1	18
64	A review of accelerometer-derived physical activity in the idiopathic inflammatory myopathies. <i>BMC Rheumatology</i> , 2019, 3, 41.	0.6	18
65	211...Is HLA-B27 a predictor of treatment response to biologics in psoriatic arthritis?. <i>Rheumatology</i> , 2019, 58, .	0.9	2
66	219...Converting patients with chronic myositis from maintenance intravenous immunoglobulin therapy to rituximab in England: a potential saving of £1.7 million per year. <i>Rheumatology</i> , 2019, 58, .	0.9	0
67	221...Quantitative strength profiling in inclusion body Myositis: faster deterioration in males and positive associations with functional assessment tools. <i>Rheumatology</i> , 2019, 58, .	0.9	0
68	222...Investigating the sensitivity and specificity of the myositis profile-4 EUROLINE assay. <i>Rheumatology</i> , 2019, 58, .	0.9	0
69	E086...Clinical and serological features of increased interferon-alpha activity in an unselected connective tissue disease cohort. <i>Rheumatology</i> , 2019, 58, .	0.9	0
70	Type I interferon in patients with systemic autoimmune rheumatic disease is associated with haematological abnormalities and specific autoantibody profiles. <i>Arthritis Research and Therapy</i> , 2019, 21, 147.	1.6	20
71	Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the <sc>UK</sc> Clinical Practice Research Datalink. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1353-1361.	2.3	44
72	Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 996-1002.	0.5	81

#	ARTICLE	IF	CITATIONS
73	Discrepancy between solid-phase immunoassays and immunoprecipitation in detecting anti-TIF1 gamma in patients with myositis. <i>Rheumatology</i> , 2019, 58, .	0.9	0
74	Comparison of Three Immunoassays for the Detection of Myositis Specific Antibodies. <i>Frontiers in Immunology</i> , 2019, 10, 848.	2.2	54
75	Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. <i>Journal of Autoimmunity</i> , 2019, 101, 48-55.	3.0	184
76	The Potential Benefits of Certolizumab Pegol in Patients with Concurrent Psoriatic Arthritis and Chronic Plaque Psoriasis: A Case Series and Review of the Literature. <i>Dermatology and Therapy</i> , 2019, 9, 373-381.	1.4	2
77	Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review. <i>Autoimmunity Reviews</i> , 2019, 18, 535-541.	2.5	26
78	[18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 657-662.	0.5	24
79	Genetics of idiopathic inflammatory myopathies: insights into disease pathogenesis. <i>Current Opinion in Rheumatology</i> , 2019, 31, 611-616.	2.0	18
80	Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases. <i>Rheumatology</i> , 2019, 58, 889-896.	0.9	35
81	The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis. <i>Rheumatology</i> , 2019, 58, 650-655.	0.9	66
82	The performance of the European League Against Rheumatism/American College of Rheumatology idiopathic inflammatory myopathies classification criteria in an expert-defined 10 year incident cohort. <i>Rheumatology</i> , 2019, 58, 468-475.	0.9	22
83	Rapamycin for inclusion body myositis: targeting non-inflammatory mechanisms. <i>Rheumatology</i> , 2019, 58, 375-376.	0.9	10
84	Assessment of two screening tools to identify psoriatic arthritis in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1530-1534.	1.3	11
85	Idiopathic inflammatory myopathies. <i>Medicine</i> , 2018, 46, 140-145.	0.2	3
86	Splicing variant of <i>WDFY4</i> augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 602-611.	0.5	51
87	Using serum troponins to screen for cardiac involvement and assess disease activity in the idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2018, 57, 1041-1046.	0.9	32
88	Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far. <i>Rheumatology</i> , 2018, 57, 1896-1907.	0.9	43
89	The EuroMyositis registry: an international collaborative tool to facilitate myositis research. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 30-39.	0.5	183
90	Impact of Disease Severity, Illness Beliefs, and Coping Strategies on Outcomes in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2018, 70, 295-302.	1.5	22

#	ARTICLE	IF	CITATIONS
91	i169â€fResearch update. Rheumatology, 2018, 57, .	0.9	0
92	O23â€fThe incidence of adult idiopathic inflammatory myopathies at a UK specialist neuromuscular centre: a ten-year epidemiology study. Rheumatology, 2018, 57, .	0.9	0
93	THU0013â€f...Downregulation of microrna may contribute to activation of the interferon signalling pathway in the idiopathic inflammatory myopathies. , 2018, , .		0
94	Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab. BMJ Case Reports, 2018, 2018, bcr-2017-223249.	0.2	11
95	i117â€fMICHAEL MASON WINNER 2018. Rheumatology, 2018, 57, .	0.9	0
96	122â€fHigh burden of immunosuppressant use in undifferentiated connective tissue disease: results from the Lupus Extended Autoimmune Phenotype Study (LEAP) cohort. Rheumatology, 2018, 57, .	0.9	0
97	Increasing incidence of adult idiopathic inflammatory myopathies in the City of Salford, UK: a 10-year epidemiological study. Rheumatology Advances in Practice, 2018, 2, rky035.	0.3	15
98	169â€fSecukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through three years: long-term data from the FUTURE 1 and FUTURE 2 studies. Rheumatology, 2018, 57, .	0.9	0
99	O67â€fA regional survey and audit of service provision for giant cell arteritis. Rheumatology, 2018, 57, .	0.9	0
100	Recent developments in classification criteria and diagnosis guidelines for idiopathic inflammatory myopathies. Current Opinion in Rheumatology, 2018, 30, 606-613.	2.0	17
101	253â€fSignatures of microbial and autoantibody epitopes in idiopathic inflammatory myopathies. Rheumatology, 2018, 57, .	0.9	0
102	Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1-Î³ autoantibodies in adult patients with myositis. Arthritis Research and Therapy, 2018, 20, 117.	1.6	16
103	127â€fQuality of life in patients with connective tissue diseases: results from the Lupus Extended Autoimmune Phenotype (LEAP) study. Rheumatology, 2018, 57, .	0.9	1
104	117â€fAnti-TIF-1 antibody positivity is associated with a five-fold increase in cancer risk in the idiopathic inflammatory myopathies. Rheumatology, 2018, 57, .	0.9	0
105	OP0148â€f...A validation of the 2017 eular/acr idiopathic inflammatory myopathies classification criteria in an expert-defined single-centre ten year incident cohort. , 2018, , .		0
106	SP0041â€f...Win session: what is new in the treatment of myositis?., 2018, , .		0
107	FRIO455â€f...Increasing incidence of adult idiopathic inflammatory myopathies: a ten-year uk epidemiological study. , 2018, , .		0
108	Immuneâ€fArray Analysis in Sporadic Inclusion Body Myositis Reveals HLAâ€f“DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum. Arthritis and Rheumatology, 2017, 69, 1090-1099.	2.9	41



#	ARTICLE	IF	CITATIONS
109	High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 208-213.	0.5	49
110	Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. <i>RMD Open</i> , 2017, 3, e000314.	1.8	29
111	Cytosolic 5â€²-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 862-868.	0.5	71
112	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2017, 69, 898-910.	2.9	52
113	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1955-1964.	0.5	754
114	Serum muscle damage markers in the idiopathic inflammatory myopathies: quantifying disease activity and identifying cardiac involvement. <i>Neuromuscular Disorders</i> , 2017, 27, S39-S40.	0.3	1
115	Idiopathic inflammatory myopathies â€” a guide to subtypes, diagnostic approach and treatment. <i>Clinical Medicine</i> , 2017, 17, 322-328.	0.8	39
116	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. <i>RMD Open</i> , 2017, 3, e000507.	1.8	115
117	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. <i>Arthritis and Rheumatology</i> , 2017, 69, 2271-2282.	2.9	391
118	11.â€¦A comparative study of the clinical features of dermatomyositis in child and in adult patients where the Anti-Mi-2 antibody is present. <i>Rheumatology</i> , 2017, 56, .	0.9	0
119	Response to: â€”Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteriaâ€” by Cavagna et al. <i>Annals of the Rheumatic Diseases</i> , 2017, 77, annrheumdis-2017-212382.	0.5	2
120	PO203â€¦Assessing disease activity and cardiac involvement in myositis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, A65.2-A65.	0.9	0
121	Rheumatology training in Poland vs. United Kingdom. <i>Reumatologia</i> , 2017, 3, 120-124.	0.5	1
122	A Literature Review of Eosinophilic Fasciitis with an Illustrative Case. <i>Current Rheumatology Reviews</i> , 2017, 13, 113-120.	0.4	4
123	Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease. <i>Reumatologia</i> , 2016, 1, 35-37.	0.5	5
124	Distress, misperceptions, poor coping and suicidal ideation in psoriatic arthritis: a qualitative study. <i>Rheumatology</i> , 2016, 55, 1047-1052.	0.9	13
125	Drug-specific risk, and associated factors, of vasculitis-like events in patients exposed to tumour necrosis factor alpha inhibitor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA). <i>Lancet, The</i> , 2016, 387, S55.	6.3	1
126	Simple tool in a complex case: use of the nailfold capillaroscopy. <i>Kidney International</i> , 2016, 89, 1168.	2.6	1



#	ARTICLE	IF	CITATIONS
127	A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice. <i>Rheumatology</i> , 2016, 55, 2131-2137.	0.9	14
128	Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis. <i>Neurobiology of Aging</i> , 2016, 47, 218.e1-218.e9.	1.5	40
129	The risk of postoperative complications in psoriasis and psoriatic arthritis patients on biologic therapy undergoing surgical procedures. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 86-91.	1.3	24
130	Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels. <i>Rheumatology</i> , 2016, 55, 2050-2055.	0.9	14
131	The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome. <i>Rheumatology</i> , 2016, 55, 2277-2278.	0.9	16
132	Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies. <i>Arthritis Research and Therapy</i> , 2016, 18, 156.	1.6	4
133	New developments in genetics of myositis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 651-656.	2.0	21
134	Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study. <i>Journal of Rheumatology</i> , 2016, 43, 1713-1717.	1.0	77
135	Disease specificity of autoantibodies to cytosolic 5â€²-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 696-701.	0.5	116
136	Proposal for a Candidate Core Set of Fitness and Strength Tests for Patients with Childhood or Adult Idiopathic Inflammatory Myopathies. <i>Journal of Rheumatology</i> , 2016, 43, 169-176.	1.0	14
137	Scalp Necrosis Associated with Giant-Cell Arteritis. <i>New England Journal of Medicine</i> , 2016, 374, e6.	13.9	5
138	Pheochromocytoma in association with focal dermatomyositis. <i>Rheumatology</i> , 2016, 55, 953-954.	0.9	1
139	Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1558-1566.	0.5	127
140	Developing standardised treatment for adults with myositis and different phenotypes: an international survey of current prescribing preferences. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 880-884.	0.4	7
141	Exploring new mechanisms of weakness-induction, further dissection of clinical phenotypes and identification of new biomarkers in the idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , 2015, 27, 577-579.	2.0	0
142	The role of microRNAs in the idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , 2015, 27, 608-615.	2.0	31
143	O10.â€¢Risk and Characteristics of Drug-Induced Lupus in Patients Exposed to Tumour Necrosis Factor-Î± Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2015, , .	0.9	0
144	Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 795-798.	0.5	74

#	ARTICLE	IF	CITATIONS
145	Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. <i>Lancet, The</i> , 2015, 385, S48.	6.3	18
146	Clinical Utility of Random Anti-Tumor Necrosis Factor Drug-Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 2011-2019.	2.9	90
147	Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. <i>Genes and Immunity</i> , 2015, 16, 470-480.	2.2	103
148	Gene-Gene and Gene-Environment Interactions in Defining Risk and Spectrum of Phenotypes in Idiopathic Inflammatory Myopathies. , 2014, , 115-132.		0
149	Phenotype Standardization for Statin-Induced Myotoxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 470-476.	2.3	166
150	GATM gene variants and statin myopathy risk. <i>Nature</i> , 2014, 513, E1-E1.	13.7	30
151	Development and Testing of New Candidate Psoriatic Arthritis Screening Questionnaires Combining Optimal Questions From Existing Tools. <i>Arthritis Care and Research</i> , 2014, 66, 1410-1416.	1.5	21
152	Psoriatic arthritis screening tools: study design and methodologic challenges - reply from authors. <i>British Journal of Dermatology</i> , 2014, 170, 995-996.	1.4	0
153	Genotyping of immune-related genetic variants identifies <i>TYK2</i> as a novel associated locus for idiopathic inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1750-1752.	0.5	25
154	The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. <i>Rheumatology</i> , 2014, 53, 213-222.	0.9	177
155	Unmasking of axial spondyloarthritis and oligoarthritis following discontinuation of tumour necrosis factor inhibitor therapy for psoriasis. <i>Journal of Dermatological Treatment</i> , 2014, 25, 61-62.	1.1	1
156	Strategies for Evaluating Idiopathic Inflammatory Myopathy Disease Susceptibility Genes. <i>Current Rheumatology Reports</i> , 2014, 16, 446.	2.1	5
157	Testing the role of vitamin D in response to antitumour necrosis factor $\hat{I}\pm$ therapy in a UK cohort: a Mendelian randomisation approach. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 938-940.	0.5	6
158	Effectiveness of switching between biologics in psoriatic arthritis- results of a large regional survey. <i>Clinical Medicine</i> , 2014, 14, 95-96.	0.8	10
159	Effect of immunogenicity on efficacy of long-term treatment of rheumatoid arthritis with adalimumab. <i>Lancet, The</i> , 2014, 383, S60.	6.3	1
160	OP0235...Genetic Risk Factors in Idiopathic Inflammatory Myopathies Are Shared with Other Autoimmune Disorders in European Populations. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 151.1-151.	0.5	0
161	SAT0052...Influence of Immunogenicity and Drug Levels on the Efficacy of Long-Term Treatment of Rheumatoid Arthritis with Adalimumab and Etanercept: A Uk-Based Prospective Study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 608.1-608.	0.5	7
162	Rituximab-associated Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, E41-E43.	0.9	28

#	ARTICLE	IF	CITATIONS
163	Statin-induced necrotizing myositis – A discrete autoimmune entity within the –statin-induced myopathy spectrum–. Autoimmunity Reviews, 2013, 12, 1177-1181.	2.5	74
164	Ustekinumab for psoriatic arthritis: close to the PSUMMIT?. Lancet, The, 2013, 382, 748-749.	6.3	2
165	Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST) Tj ETQq1 1 0,784314 rgrBT /Ove	1.4	130
166	Genome–Wide Association Study of Dermatomyositis Reveals Genetic Overlap With Other Autoimmune Disorders. Arthritis and Rheumatism, 2013, 65, 3239-3247.	6.7	113
167	Successful use of tocilizumab in a patient with psoriatic arthritis. Rheumatology, 2013, 52, 1728-1729.	0.9	33
168	Entering a new phase of immunogenetics in the idiopathic inflammatory myopathies. Current Opinion in Rheumatology, 2013, 25, 735-741.	2.0	19
169	Editorial. Current Opinion in Rheumatology, 2013, 25, 726-728.	2.0	2
170	Time for a –joint–™ approach?. British Journal of Dermatology, 2013, 168, 683-684.	1.4	7
171	SAT0189–Use of Anti-200/100 Antibody in the Evaluation of Statin Induced Myositis: Experience of a UK Based Tertiary Myositis-Referral Centre. Annals of the Rheumatic Diseases, 2013, 72, A645.1-A645.	0.5	0
172	Polymyositis and dermatomyositis. , 2013, , 1009-1020.		4
173	Polymyositis and dermatomyositis. , 2013, , 1009-1020.		2
174	Association of an MHC Class II Haplotype with Increased Risk of Polymyositis in Hungarian Vizsla Dogs. PLoS ONE, 2013, 8, e56490.	1.1	16
175	Genetic association study of NF-–B genes in UK Caucasian adult and juvenile onset idiopathic inflammatory myopathy. Rheumatology, 2012, 51, 794-799.	0.9	30
176	Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study. Annals of the Rheumatic Diseases, 2012, 71, 961-965.	0.5	100
177	Recent advances in the immunogenetics of idiopathic inflammatory myopathy. Arthritis Research and Therapy, 2011, 13, 216.	1.6	38
178	Academic training in rheumatology in 2009: a UK trainee survey. Clinical Medicine, 2011, 11, 434-437.	0.8	4
179	Quantitative nailfold video capillaroscopy in patients with idiopathic inflammatory myopathy. Rheumatology, 2010, 49, 1699-1705.	0.9	37
180	Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Annals of the Rheumatic Diseases, 2009, 68, 1621-1625.	0.5	161

#	ARTICLE	IF	CITATIONS
181	HLA-DPB1 associations differ between DRB1*03 positive anti-Jo-1 and anti-PM-Scl antibody positive idiopathic inflammatory myopathy. <i>Rheumatology</i> , 2009, 48, 1213-1217.	0.9	41
182	Autoantibodies to a 140 kDa protein in juvenile dermatomyositis are associated with calcinosis. <i>Arthritis and Rheumatism</i> , 2009, 60, 1807-1814.	6.7	206
183	Defining cancer risk in dermatomyositis. Part I. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 451-455.	0.6	54
184	Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 561-565.	0.6	38
185	An update on the immunogenetics of idiopathic inflammatory myopathies: major histocompatibility complex and beyond. <i>Current Opinion in Rheumatology</i> , 2009, 21, 588-593.	2.0	20
186	The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients. <i>Arthritis and Rheumatism</i> , 2008, 58, 3247-3254.	6.7	56
187	Clinical, serological and HLA profiles in non-Caucasian UK idiopathic inflammatory myopathy. <i>Rheumatology</i> , 2008, 48, 591-592.	0.9	11
188	The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1345-1349.	0.5	291
189	HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. <i>Rheumatology</i> , 2007, 46, 1786-1791.	0.9	102
190	Tumour necrosis factor- $\alpha$ single nucleotide polymorphisms are not independent of HLA class I in UK Caucasians with adult onset idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2007, 46, 1411-1416.	0.9	44
191	Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. <i>Rheumatology</i> , 2007, 47, 324-328.	0.9	186
192	Interferon-gamma and interleukin-4 gene polymorphisms in Caucasian idiopathic inflammatory myopathy patients in UK. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 970-973.	0.5	32
193	In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. <i>Arthritis Research and Therapy</i> , 2006, 8, R13.	1.6	110
194	Serum alanine aminotransferase elevations correlate with serum creatine phosphokinase levels in myositis. <i>Rheumatology</i> , 2006, 45, 487-488.	0.9	19
195	Monocyte chemoattractant protein-1 single nucleotide polymorphisms do not confer susceptibility for the development of adult onset polymyositis/dermatomyositis in UK Caucasians. <i>Rheumatology</i> , 2006, 46, 604-607.	0.9	15
196	Have recent immunogenetic investigations increased our understanding of disease mechanisms in the idiopathic inflammatory myopathies?. <i>Current Opinion in Rheumatology</i> , 2004, 16, 707-713.	2.0	24
197	Wegener's granulomatosis and rheumatoid arthritis overlap. <i>British Journal of Rheumatology</i> , 2002, 41, 588-589.	2.5	21
198	The effect of the Covid-19 pandemic on illness perceptions of psoriasis and the role of depression: Findings from a cross-sectional study. <i>Skin Health and Disease</i> , 0, , .	0.7	1

#	ARTICLE	IF	CITATIONS
199	Associations between psoriatic arthritis and mental health among patients with psoriasis: A replication and extension study using the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). <i>Skin Health and Disease</i> , 0, , .	0.7	2